Sign In
Buy JAGX
$2.92
-0.300 (-9.32%)
At Close: Jun 03, 2026
Company's Canalevia®-CA1 prescription drug is FDA conditionally approved for treatment of chemotherapy-induced diarrhea (CID) in dogs and is the first and only treatment for CID in dogs to receive an
New Innovators with Jane King Interview with Jaguar Health CEO Lisa Conte Spotlights Company's Near-Term Commercial & Development Milestones
10:00am, Wednesday, 04'th Sep 2024
Click here to view interview video Paramount near-term activities include planned October 2024 commercial launch of FDA-approved oral mucositis prescription product Gelclair ® and results from indepe
Patent Issued in Jordan Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)
10:00am, Tuesday, 27'th Aug 2024
New patent issued for core rare disease target indication for crofelemer Napo has approximately 230 patents issued and pending Jaguar is supporting independent investigator-initiated proof-of-concept
Key Collaborator of Jaguar Health Joint Venture Magdalena Biosciences Receives Prestigious Alzheimer's Association Award
10:00am, Tuesday, 20'th Aug 2024
Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health, is focused on developing novel prescription psychoactive plant-based medicines for various mental health indications SAN FR
Issuance of New Hong Kong Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)
10:00am, Monday, 19'th Aug 2024
New patent issued for core rare disease target indication for crofelemer Napo has approximately 230 patents issued and pending Jaguar is supporting independent investigator-initiated proof-of-concept
Jaguar Health, Inc. (JAGX) Q2 2024 Earnings Call Transcript
02:57pm, Tuesday, 13'th Aug 2024
Jaguar Health, Inc. (NASDAQ:JAGX ) Q2 2024 Earnings Conference Call August 13, 2024 8:30 AM ET Company Participants Lisa Conte - Founder, President & Chief Executive Officer Pravin Chaturvedi - Chief
Jaguar Health Reports Second Quarter 2024 Financial Results
08:00am, Tuesday, 13'th Aug 2024
The combined net Q2 2024 revenue of approximately $2.72 million for prescription and non-prescription products increased approximately 16% versus net Q1 2024 revenue of $2.35 million and 2.0% versus n
Jaguar to explore approval pathway for crofelemer in breast and lung cancer based on phase 3 results Click here to register for investor webcast Company plans to file its Earnings Report on August 13,
Dr. Elisabetsky is also an advisor to Magdalena Biosciences , the joint venture formed by Jaguar and Filament Health focused on identifying the next generation of plant-based first-in-class agents for
It is estimated that 10-15% of people in the United States have IBS SAN FRANCISCO, CA / ACCESSWIRE / August 1, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") family company Napo Pharmaceuticals (
Issuance of New European Patent Bolsters IP Protection for Jaguar Health in the Treatment of Congenital Diarrheal Disorders (CDDs)
10:00am, Wednesday, 31'st Jul 2024
New patent issued for core rare disease target indication for crofelemer Jaguar has approximately 200 patents issued and pending Jaguar is supporting investigator-initiated proof-of-concept studies of
Why Is Jaguar Health (JAGX) Stock Down 55% Today?
12:30pm, Tuesday, 23'rd Jul 2024
Jaguar Health (NASDAQ: JAGX ) stock is taking a beating on Tuesday after the commercial-stage pharmaceuticals company reported results from a Phase 3 clinical trial. This trial covers the use of crofe
Jaguar Health's stock slides 68% after cancer trial fails to meet main goal
08:41am, Tuesday, 23'rd Jul 2024
Jaguar Health Inc.'s stock JAGX, +0.23% tumbled 68% early Tuesday, after the biotech said a late-stage trial of a cancer drug failed to meet its main goal across all tumor types. San Francisco-based J
Jaguar Health Reports Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer
08:00am, Tuesday, 23'rd Jul 2024
Initial results of unprecedented trial including 10 different tumor types indicate that OnTarget did not meet its primary endpoint across all tumor types. Trial did reveal clinically relevant signals
Webcast on Tuesday, July 23rd at 8:30 AM Eastern will include updates on Jaguar's cancer supportive care portfolio, including participation from Jaguar scientific team, patient advocates, and leading
